• June 2015 - Initiated Clinical Study to Triage ED patients with the PliNOSa™ K-1600 EIA kit to expand marketing claims.

  • April 2015 - Established relationship with Authorized Representitive in the EU to allow the sale and distribution of PliNOSa™ K-1600 EIA kit.

  • December 2014 - Recieved ISO 13485 Certification.

  • November 2014 - Exhibited at Medica 2014 in Düsseldorf Germany.

  • April 2014 - Started the implementation of a Quality Management System to meet ISO 13485 regulatory requirements.

  • September 2013 - Pilot Clinical Study on the PliNOSa™ K-1600 EIA kit completed.

  • June 2013 - Scaled up manufacturing capabilities for PliNOSa™ K-1600 EIA kit.

  • January 2013 - Pilot Clinical Study started to obtain FDA approval of first reliable and accurate IVD test for sepsis

  • September 2012 - Filed PCT patent application with WIPO for Panel of Sepsis Biomarkers

  • September 2012 - Dr. Webber named "Researcher of the Year" by NevBio

  • July 2012 - Japanese Patent #5048207 issued extending in vitro diagnostic coverage

  • September 2011 - Filed patent application with the USPTO for Panel of Sepsis Biomarkers

  • October 2010 - Patent #EP1412471 extending in vitro diagnostic coverage issued in the UK, Ireland, Germany, France, Switzerland and Italy

  • June 2010 - $2.6 million RC3 grant awarded by NIGMS to obtain FDA approval for plasma iNOS test as an in vitro diagnostic for the onset of sepsis

  • September 2009 – Notice of Allowance received from European Patent Office for “Apparatus and method for determining the onset and presence of sepsis conditions”

  • April 2009 – Touro University of Nevada Medical School, Henderson, NV: Invited Research Lecture

  • October 2008 – Nevada Biotechnology & Bioscience Consortium, Las Vegas, NV: Invited Research Presentation

  • June 2008 – European Patent Office Patent # EP1012605 issued. "Immunoassay method employing monoclonal antibody reactive to human iNOS"

  • May 2008 – Japan Patent Office Patent # 4117911 issued. "Immunoassay method employing monoclonal antibody reactive to human iNOS"

  • May 2008 – LifeScienceFest 2008, University of California, Davis, CA: Invited Presentation
  • April 2008 – Notice of Allowance received from Janapese Patent Office for “Immunoassay method employing monoclonal antibody reactive to human iNOS”
  • February 2008 – Frost & Sullivan’s Venture Connection 2008, San Francisco, CA: Invited Presentation
  • December 2007 - Analysis of clinical trial data shows plasma iNOS has a positive predictive value of greater than 96% for organ dysfunction associated with sepsis

  • November 2007- Notice of Allowance received from European Patent Office for “Immunoassay method employing monoclonal antibody reactive to human iNOS”

  • April 2007 - BioFinance 2007, Toronto, Canada: Invited Presentation

  • April 2007 - U.S.A. Patent # 7,198,904 issued. "Immunoassay method employing monoclonal antibody reactive to human iNOS"

  • November 2006 - Australian patent #2001280912 issued. "Apparatus and method for determining the onset and presence of sepsis conditions"

  • September 2006 - 46th ICAAC conference, San Francisco, CA: Poster presentation

  • September 2006 - Walter Reed Army Institute of Research, Washington, DC: Invited Presentation

  • June 2006 - Tri-Service General Hospital, Taipei, Taiwan: Invited Lecture

  • June 2006 - National Defense Medical Center, Taipei, Taiwan: Invited Lecture

  • June 2006 - Academia Sinica, Institute of Biomedical Sciences, Taipei, Taiwan: Invited Lecture

  • May 2006 - 27th American Society for Apheresis Conference, Las Vegas, NV: Poster presentation

Home | News | R&D Vision | President's Message | Achievements | Leadership Team | Technology | Contact